Science, www.science.org/doi/10.1126/sciadv.adn8662Environmental researchBreakthrough: Bio-based foam absorbs 99% o...Chinese researchers headed by Prof. Dr. Hongbing Deng from Wuhan University report the were able to absorb up to 99.9% of microplastics in water, which could help solve one of the most pressing environmental … more ➔
Cradle.bioFinancingCradle Secures $73m Series B to Accelerate...The Dutch-Swiss company with operations also in Zurich, Switzerland, has raised US$73m in a Series B and will continue to expand its AI research, sales, and operations teams. The new announcement comes … more ➔
Roche, Herzog&De MeuronM&ARoche makes takeover bid for Poseida Thera...Genentech, the US arm of Swiss-based Roche AG, plans to acquire its long-time partner in allogeneic CAR-T blood cancer and gene therapies, Poseida Therapeutics Inc, for up to US$1.5bn. more ➔
PharmaMar SAMarket AuthorisationEC ordered to pay cost of PharmaMar vs EMA...The General Court of the EU orders the European Commission to pay the costs in the case of Aplidin® against the Spanish company PharmaMar SA, in which an EU marketing authorisation was not granted due … more ➔
NOD-Proteindesign.Andreas Heddergott/TUM.jpgProtein EngineeringNew method set to speed up protein designResearcher from China, Germany and the US have developed a method for designing large new proteins with pre-defined properties in the lab using Alphafold2. more ➔
CertestDrug deliveryCircio Holding ASA inks collaboration agre...Circio Holding ASA has inked a collaboration with Certest Biotec, SL to find and test circVec LNP-formulations to deliver its circular RNA therapeutics to target tissues for gene therapies. more ➔
ConsiliumNovel FoodCountry alliance calls for EU protein str...A dispute is brewing in Europe over climate-friendly protein production in fermenters between EU member states that are in favour of or against protein production independent of agricultural land. Germany, … more ➔
FinanancingATB Therapeutics raises €54m in Series A...Belgian ADC specialist ATB Therapeutics BV has kicked off with €54m from EQT Life Sciences and MRL Ventures Fun to push its payload technology towards clinical development. more ➔
Innate Pharma SAAntibody engineeringTetraspecific B/NK cell better than T cell...Innate Pharma SA has presented promising preclinical data of its tetraspecific antibody-based B and NK cell engager IPH6501, a novel approach to treat B cell non-Hodgkin lymphoma (B-NHL). more ➔
AdaptimmuneClinical trialsAdaptimmune nears second approval for TCR-...After meeting the primary endpoints of a pivotal Phase II trial, UK-based Adaptimmune Ltd. is submitting an FDA Biologics License Application for its autologous T-cell receptor therapy (TCR-T) Lete-cel … more ➔